Incidental Cancer in Familial Adenomatous Polyposis

Sponsor

Dr. Ersin Arslan Education and Training Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT05171426

Collaborator

(none)

Enrollment

Location

37.7

Actual Duration (Months)

1.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Condition or Disease	Intervention/Treatment	Phase
Cancer

Detailed Description

Colectomy is life-saving in patients with familial adenomatous polyposis (FAP) because cancer development is inevitable in individuals with this disease. In this study, we aimed to determine the incidence of incidental malignancy in surgical specimens from patients who underwent colectomy for FAP. The files of patients diagnosed with FAP who underwent surgery in our clinic between 2010 and 2020 were retrospectively reviewed. Definitive surgery was performed in patients with histopathological malignancy identified in colonoscopic biopsies in the preoperative period, while prophylactic surgery was performed in patients without malignancy. The incidence of incidental malignancy in histopathological specimens from patients who underwent prophylactic colectomy was determined. Prophylactic colectomy should be performed in patients with FAP, as colorectal cancer transformation is inevitable in these individuals. The possibility of incidental cancer identified via histopathological analysis of colectomy specimens should be kept in mind in these patients.

Study Design

Study Type:

Observational

Actual Enrollment :

55 participants

Observational Model:

Other

Time Perspective:

Retrospective

Official Title:

Incidental Cancer in Colectomy Specimens From Patients With Familial Adenomatous Polyposis

Actual Study Start Date :

Jan 1, 2018

Actual Primary Completion Date :

Jan 15, 2019

Actual Study Completion Date :

Feb 20, 2021

Arms and Interventions

Arm	Intervention/Treatment
incidental cancer familial adenomatous polyposis with incidental cancer

Outcome Measures

Primary Outcome Measures

incidental cancer [2 or 3 week]
Familial Adenomatous Polyposis with cancer

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

diagnosed with Familial Adenomatous Polyposis

Exclusion Criteria:

did not receive surgical treatment
data deficiencies

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Dr. Ersin Arslan Training and Resource Hospital	Gaziantep		Turkey

Sponsors and Collaborators

Dr. Ersin Arslan Education and Training Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Ufuk Uylas, Primary investigator, Tepecik Training and Research Hospital

ClinicalTrials.gov Identifier:

NCT05171426

Other Study ID Numbers:

2018/16-20

First Posted:

Dec 28, 2021

Last Update Posted:

Dec 28, 2021

Last Verified:

Dec 1, 2021

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Ufuk Uylas, Primary investigator, Tepecik Training and Research Hospital

familial adenomatous polyposis

Additional relevant MeSH terms:

Adenomatous Polyposis Coli

Study Results

No Results Posted as of Dec 28, 2021